Spectrophotometric Method for the Determination of Oxaliplatin in Pure and Dosage Forms

G.SRINUBABU¹, D.PUNDARIKA RAO², L. SRIDHAR¹
and J.V.L.N. SESHAGIRI RAO^{1*}

¹University College of Pharmaceutical Sciences,

²Department of Geo-engineering, College of Engineering.
Andhra University, Visakhapatnam –530003 (A.P.) INDIA.

Received 2 October 2005; Accepted 23 January 2006

Abstract: A simple and reproducible spectrophotometric method has been developed for the estimation of Oxaliplatin in pure and dosage forms. The method is based on the reaction of the drug with 1, 10 Phenanthroline in presence of ferric chloride, which forms a blood red colored complex exhibiting maximum absorption at 520 nm.

Key words: Oxaliplatin, spectrophotometric method

Introduction

Oxaliplatin ([(*1R*, *2R*)-1,2-cyclohexanediamine-*N*, *N*] oxalato (2-)-*O*, *O* -platinum) is a novel platinum complex which in combination with other chemotherapeutics has a significant cytostatic activity for metastatic colon cancer¹. The pharmacokinetics of Oxaliplatin has so far almost exclusively been based on analysis of the platinum content in plasma and ultra filtrate using flameless atomic absorption spectroscopy (FAAS) or inductively coupled plasma mass spectrometry (ICPMS)². However, analytical techniques measuring the concentration of platinum will codetermine the parent compound as well as other cytotoxic and biologically inactive biotransformation products. Recently, the kinetics of Oxaliplatin in plasma ultra filtrate from patients was studied using liquid chromatography followed by fraction collection and measuring the platinum content by FAAS³. Liquid chromatography with porous graphitic carbon (PGC) has previously been utilized for the preparative isolation⁴⁻⁶ and quantitative analysis⁷⁻⁹ of Pt-containing cytotoxic agents in

pure aqueous solutions. Until now there is no single spectrophotometric method available in the literature for oxaliplatin determination.

26 J.V.L.N. SESHAGIRI RAO *et al.*

The authors now report the development of simple and reproducible spectrophotometric method for its determination in pure and dosage forms. Spectrophotometric parameters were established for standardization of the method by statistical analysis of data.

Experimental

All the chemicals used were of analytical grade. Solution of 1, 10 Phenanthroline monohydrate (0.2 %) and ferric chloride (0.5 %) were prepared using double distilled water. Spectral and absorbance measurements were made on an Elico UV-Visible spectrophotometer (Model 64) with 10 mm-matched quartz cells.

Preparation of standard solution

100 mg of pure Oxaliplatin was accurately weighed and dissolved in 100 ml of double distilled water to get a concentration of 1 mg/ml. This solution was further diluted with water to get a working standard solution of 100 µg/ml.

Preparation of sample solution

A commercial brand of injection was chosen. For this, 5 injections were taken and from that Oxaliplatin equivalent to 50 mg was transferred to a 50 ml volumetric flasks containing 25 ml methanol. The contents were allowed to stand for ½ h with intermittent sonication to ensure complete solubility of the drug and then filtered through 0.45 µm membrane filter. The volume was made to the mark with methanol. The solution is suitably diluted with methanol to get 100 µg/ml.

Method

Aliquots of standard solution were transferred into a series of 10 ml calibrated tubes. To that 0.5 ml of ferric chloride and 2.5 ml of Phenanthroline were added and heated on a boiling water bath for 15 min. contents were cooled to room temperature and 1 ml of ortho-phosphoric acid added. Finally the volume was adjusted with distilled water and absorbance was measured at 520 nm against a reagent blank prepared under identical conditions.

Results and Discussion

The optical characteristics such as Beer's law limits, Sandell's sensitivity, molar extinction coefficient, percent relative standard deviation and percent range of error were calculated for the method and the results are summarized in Table 1. The accuracy of the methods was ascertained by comparing the results of the proposed methods with that of reported method. In order to justify the reliability and suitability of proposed methods, a known amount of pure drug was added to its various pre analyzed dosage forms and was analyzed by the proposed method. The results presented in Table 2 indicate that the proposed method can be successfully applied for the analysis of Oxaliplatin in dosage forms. The additives and excipients usually present in pharmaceutical preparations did not interfere.

Chemistry of the colored species

The present method is based on the formation of blood red colored complex (λ max: 520 nm) with ferric chloride after its reduction to ferrous form. The blood red colored complex resulting from Oxaliplatin may be due to the fact that each of the two nitrogen atoms has an unshared pair of electrons that can be shared with Fe (II) ion formed by the reaction of

Oxaliplatin with Fe (III). Three such molecules of PTL attach themselves by means of dative bonds (Ferroin complex).

Table 1. Optical characteristics

Parameters	Value
Beer's law limits (μg)	8-32
Sandell's sensitivity ($\mu\text{g}/\text{cm}_2/0.001$ absorbance unit)	0.049
Molar absorbtivity	8070
% Relative standard deviation	0.3467
% Range of error	
0.05 Confidence limits	0.285
0.01 Confidence limit	0.484
Correlation coefficient	0.99912
Regression equation ($Y=b+ac$)*	
Slope (a)	0.021
Intercept (b)	-0.0066

*where C is the concentration in $\mu\text{g}/\text{ml}$ and Y is absorbance unit.

Table 2. Assay of Oxaliplatin in Pharmaceutical Formulations

Sample	Labelled amount (mg)	Amount obtained (mg) reference method*	proposed method	% recovery by the proposed method
1. Oxaliplatin	100	99.97	100.13	100.13

*UV method developed by authors

Acknowledgements

The authors are thankful to Dr. Reddys, for providing a gift sample of Oxaliplatin for this investigation.

References

1. Misset J L, Bleiberg H, Sutherland W, Bekradda M and Cvitkovic E, *Crit. Rev. Oncol. Hematol.*, 2000, **35**, 75
2. Graham M A, Lockwood G F, Greenslade D, Brienza S, Bayssas M and Gamelin E, *Clin. Cancer Res.*, 2000, **6**, 1205.
3. Shord S S, Bernard S A, Lindley C, Blodgett A, Mehta V, Churchel M A, Poole M, Pescatore S L, Luo F R and Chaney S G, *Anticancer Res.*, 2002, **22**, 2301.
4. Ehrsson H, Wallin I, Andersson A and Edlund P O. *Anal. Chem.*, 1995, **67**, 3608.
5. Yachnin J, Wallin I, Lewensohn R, Sirzen F and Ehrsson H, *Cancer Lett.*, 1998, **132**, 175
6. Ekborn A, Lindberg A, Laurell G, Wallin I, Eksborg S and Ehrsson H, *Cancer Chemother. Pharmacol.*, 2003, **51**, 36.
7. Videhult P, Yachnin J, Jerremalm E, Lewensohn R and Ehrsson H, *Cancer Lett.*, 2002, **180**, 191.
8. Jerremalm E, Videhult P, Alvelius G, Griffiths W J, Bergman T, Eksborg S and Ehrsson H, *J. Pharm. Sci.* 2002, **91**, 2116.
9. Jerremalm E, Eksborg S and Ehrsson H, *J. Pharm. Sci.*, 2003, **92**, 436.